Article
- The EMBO Journal (2005) 24, 108 - 119
- doi:10.1038/sj.emboj.7600506
Published online: 9 December 2004
Subject Categories:
Multiple activities contribute to Pc2 E3 function
Michael H Kagey1, Tiffany A Melhuish1, Shannon E Powers1 and David Wotton1
- Department of Biochemistry and Molecular Genetics, Center for Cell Signaling, University of Virginia, Charlottesville, VA, USA
Correspondence to:
David Wotton, Center for Cell Signaling, University of Virginia, Room 7161, Hospital West, 800577 HSC, Charlottesville, VA 22908, USA. Tel.: +1 434 243 6752; Fax: +1 434 924 1236; E-mail: dw2p@virginia.edu
Received 7 September 2004; Accepted 12 November 2004
Abstract
Pc2 is a polycomb protein, which has SUMO E3 activity for the corepressors CtBP and CtBP2. Here we demonstrate that, in vivo, Pc2 adapter function contributes to enhancement of CtBP sumoylation. Mutation of the CtBP binding site on Pc2 abolishes E3 activity toward CtBP. However, a carboxyl-terminal fragment of Pc2 that recruits both Ubc9 and CtBP lacks E3 activity. We identify a second domain, which, when coexpressed with the carboxyl-terminal adapter region, restores E3 function. In vitro, this domain has E3 activity in isolation, suggesting that it is a functional domain, and that adapter function is required to selectively corecruit E2 and substrate in vivo. These results demonstrate the presence of two domains in Pc2 that contribute to full in vivo E3 activity, and suggest that SUMO E3s are more than simple platforms to which E2 and substrate bind.
Keywords:
- CtBP,
- E3,
- Polycomb,
- Pc2,
- SUMO
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Nature Reviews Neuroscience Perspective (01 Oct 2002)
Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction
Nature Reviews Neuroscience Review (01 Dec 2007)
SUMO: a regulator of gene expression and genome integrity
Oncogene Review
RESEARCH
PIASx acts as an Elk-1 coactivator by facilitating derepression
The EMBO Journal Article (15 Jun 2005)
